At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in-human study of the first-in-class fatty acid synthase inhibitor, TVB-2640, as monotherapy or in combination for the treatment of patients with solid malignancies.
First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640
15th October 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now